Nr2b receptor antagonists for the treatment or prevention of migraines
OwnerChristopher Allen, Ken S. Koblan +1inventors
InventorsChristopher Allen, Ken S. Koblan, Timothy Sleeth
Life of this patent
Estimating the term…
Abstract
The present invention encompasses a method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines. The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist or a 5HT1B/1D agonist for the treatment or prevention of migraines.
Claims20
A method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines.
A pharmaceutical composition comprising an NR2B receptor antagonist and a calcitonin gene-related peptide receptor (CGRP) receptor ligand in combination with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising an NR2B receptor antagonist and a 5HT1B/D agonist in combination with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising an NR2B receptor antagonist and a leukotriene receptor antagonist in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.